Tag Archives: Amgen

Specialty Drug, Specialty Pharmacy

Biologics by McKesson Selected to Provide TRUSELTIQ and LUMAKRAS

Posted on by John Santilli
22
Jun

Biologics specialty pharmacy teams includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients

Continue reading →
Trends, Uncategorized

Outcome-Based Contracting Acceptance Grows in Market

Posted on by John Santilli
Specialty Pharma Services
03
Feb

Outcome-Based Contracting Acceptance Grows in market with the concept of taking on financial risk on complex contracts as a result of market pressure combined with more familiarity. Outcome-based contracts between pharma companies and health insurers are becoming increasingly popular. In 2016, Novartis, Amgen, and Sanofi publicized risk-sharing, value-based, outcomes-based, or pay-for-performance deals, all of which vary […]

Continue reading →
Clinical Collaborations, Uncategorized

Increasing Demand for Drug Based Outcomes

Posted on by John Santilli
Specialty Pharma Services
23
Dec

Increasing Demand for Drug Based Outcomes – Outcome-based contracts are a relatively new and growing contracting methodology focused on shifting reimbursement from volume to value. The contracts are between a health plan and manufacturer where reimbursement is dependent on pre-defined outcome metrics focused on improving patient responses/health. Currently, the relationship between the pharmaceutical manufacturer, the […]

Continue reading →